ADAM17 and cancer: In addition, there is evidence that the release of EGFR ligands from cancer associated macrophages depends on ADAM17 and it was demonstrated that myeloid EGFR activation (Figure 2b) is a prerequisite for the release of tumour-promoting IL-6 [82].